The use of growth hormone therapy in adults with Prader-Willi syndrome: A systematic review.
GH
PWS
body mass
bone
cardiovascular
growth
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
16
09
2020
received:
19
08
2020
accepted:
16
11
2020
pubmed:
10
12
2020
medline:
13
8
2021
entrez:
9
12
2020
Statut:
ppublish
Résumé
Despite clear benefits in the management of children with Prader-Willi syndrome (PWS), the role of growth hormone (GH) in adults is unclear. The aim of this study was to conduct a systematic review to evaluate the effects of GH on body composition, bone health and cardiovascular health in adults with PWS. A systematic computerized literature search of the PubMed database was conducted by two independent reviewers. Inclusion criteria were individuals over the age of 16 years with a genetic diagnosis of PWS who had received GH therapy, together with assessment of body composition, bone health or cardiovascular health. Twenty full-text papers met the inclusion criteria, encompassing 364 unique patients. No differences in body mass index (BMI) were noted, although 2 studies reported increased BMI after GH cessation. Data demonstrated statistically significant increases in lean body mass and reductions in percentage fat mass. Studies reported inconsistent effects of GH on cholesterol and echocardiography parameters. No studies reported differences in bone mineral density, although one reported improved bone geometry. Minor adverse events including pretibial oedema, headache and transient impaired glucose tolerance were reported in 7 studies. These data suggest that GH is safe and well tolerated in adults with PWS, with evidence of improvement in body composition. Further longitudinal studies are still required to investigate the effects of GH on bone and cardiovascular health. Where GH is used in adults with PWS, this should be managed by a specialist multidisciplinary team with regular monitoring initiated.
Substances chimiques
Human Growth Hormone
12629-01-5
Growth Hormone
9002-72-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
645-655Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
McCandless SE, Suh M, Yin D, et al. SUN-604 US prevalence & mortality of Prader-Willi syndrome: a population-based study of medical claims. J Endocrine Soc. 2020;4(Supplement_1).A504-A505.
Vogels A, Van Den Ende J, Keymolen K, et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet. 2004;12(3):238-240.
Grugni G, Sartorio A, Crinò A. Growth hormone therapy for Prader-Willi syndrome: challenges and solutions. Ther Clin Risk Manag. 2016;12:873.
Brambilla P, Bosio L, Manzoni P, Pietrobelli A, Beccaria L, Chiumello G. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr. 1997;65(5):1369-1374.
Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr. 1999;134(2):215-221.
Theodoro MF, Talebizadeh Z, Butler MG. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity. 2006;14(10):1685-1690.
Nakamura Y, Murakami N, Iida T, Asano S, Ozeki S, Nagai T. Growth hormone treatment for osteoporosis in patients with scoliosis of Prader-Willi syndrome. J Orthop Sci. 2014;19(6):877-882.
Patel S, Harmer JA, Loughnan G, Skilton MR, Steinbeck K, Celermajer DS. Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome. Clin Endocrinol. 2007;66(6):771-777.
Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS. Participants GHiP-WSCCGW: growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013;98(6):E1072-E1087.
Butler MG, Matthews NA, Patel N, et al. Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index. Am J Med Genet A. 2019;179(9):1826-1835.
Donze SH, Damen L, van Alfen-van der Velden J, et al. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2019;91(1):118-123.
Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol. 2012;77(1):86-93.
Lucas-Herald AK, Perry CG, Shaikh MG. Review of growth hormone therapy in adolescents and young adults with Prader-Willi syndrome. Exp Rev Endocrinol Metab. 2015;10(2):259-267.
A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI), Version 1.0.0, 24 September 2014.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Höybye C, Tauber M, Angulo MA, et al. Clinical, Organisation SABoTIPWS: Letter regarding" Prevalence of growth hormone deficiency in previously GH-treated young adults with Prader-Willi syndrome" by Donze et al. Clin Endocrinol. 2019;91(4):578-579.
Grugni G, Marzullo P, Ragusa L, et al. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. Clin Endocrinol. 2006;65(4):492-499.
Oto Y, Tanaka Y, Abe Y, et al. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome. Am J Med Genet A. 2014;164(3):671-675.
Coupaye M, Tauber M, Cuisset L, et al. Effect of genotype and previous GH treatment on adiposity in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2016;101(12):4895-4903.
Höybye C, Thoren M, Böhm B. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome. J Intellect Disabil Res. 2005;49(4):245-252.
Kuppens R, Mahabier E, Bakker N, Siemensma E, Donze S, Hokken-Koelega A. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial. Orphanet J Rare Dis. 2016;11(1):153.
Bertella L, Mori I, Grugni G, et al. Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study. J Intellect Disabil Res. 2007;51(4):302-311.
Höybye C. Inflammatory markers in adults with Prader-Willi syndrome before and during 12 months growth hormone treatment. Horm Res Paediatr. 2006;66(1):27-32.
Höybye C, Barkeling B, Espelund U, Petersson M, Thorén M. Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment. Growth Hormon IGF Res. 2003;13(6):322-327.
Olarescu NC, Jørgensen AP, Godang K, Jurik AG, Frøslie KF, Bollerslev J. Dual-energy X-ray absorptiometry is a valid method to estimatimate visceral adipose tissue in adult patients with prader-willi syndrome during treatment with growth hormone. J Clin Endocrinol Metab. 2014;99(9):E1727-E1731.
Jørgensen AP, Ueland T, Sode-Carlsen R, et al. Glucose homeostasis in adults with Prader-Willi syndrome during treatment with growth hormone: results from a 12-month prospective study. Growth Hormon IGF Res. 2014;24(1):16-21.
Höybye C, Hilding A, Jacobsson H, Thorén M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol. 2003;58(5):653-661.
Sode-Carlsen R, Farholt S, Rabben KF, et al. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(11):4943-4950.
Sode-Carlsen R, Farholt S, Rabben KF, et al. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. Growth Hormon IGF Res. 2011;21(4):185-190.
Höybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Hormon IGF Res. 2004;14(1):1-15.
Donze SH, Kuppens RJ, Bakker NE, van Alfen-van der Velden JA, Hokken-Koelega AC. Bone mineral density in young adults with Prader-Willi syndrome: a randomized, placebo-controlled, crossover GH trial. Clin Endocrinol. 2018;88(6):806-812.
Kuppens R, Bakker N, Siemensma E, Donze S, Stijnen T, Hokken-Koelega A. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial. Clin Endocrinol. 2017;86(2):297-304.
Kuppens RJ, Bakker NE, Siemensma EP, et al. Beneficial effects of GH in young adults with Prader-Willi syndrome: a 2-year crossover trial. J Clin Endocrinol Metab. 2016;101(11):4110-4116.
Marzullo P, Marcassa C, Campini R, et al. Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab. 2007;92(4):1364-1371.
Marzullo P, Marcassa C, Minocci A, et al. Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2015;100(5):2106-2114.
Longhi S, Grugni G, Gatti D, et al. Adults with Prader-Willi syndrome have weaker bones: effect of treatment with GH and sex steroids. Calcif Tissue Int. 2015;96(2):160-166.
Lafortuna CL, Minocci A, Capodaglio P, et al. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2014;99(5):1816-1824.
Gondoni L, Vismara L, Marzullo P, Vettor R, Liuzzi A, Grugni G. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. J Endocrinol Invest. 2008;31(9):765-772.
Mogul HR, Lee PD, Whitman BY, et al. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J Clin Endocrinol Metab. 2008;93(4):1238-1245.
Koizumi M, Ida S, Shoji Y, Nishimoto Y, Etani Y, Kawai M. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome. Endocr J. 2018;65:1127-1137.
Butler MG, Smith BK, Lee J, et al. Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth Hormon IGF Res. 2013;23(3):81-87.
Höybye C. Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition. Acta Paediatr. 2015;104(4):422-427.
Jørgensen A, Ueland T, Sode-Carlsen R, et al. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD. J Clin Endocrinol Metab. 2013;98(4):E753-E760.
Hoybye C, Bruun JM, Richelsen B, Flyvbjerg A, Frystyk J. Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. Eur J Endocrinol. 2004;151(4):457-462.
Höybye C, Hilding A, Marcus C, Thorén M. Growth hormone induced lipolysis during short-and long-term administration in adult Prader-Willi patients. Growth Hormon IGF Res. 2005;15(6):411-415.
Zillikens MC, Demissie S, Hsu Y-H, et al. Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nat Commun. 2017;8(1):80.
Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med. 2017;19(6):635-642.
Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation. 2003;108(21):2648-2652.
Zhu K, Briffa K, Smith A, et al. Gender differences in the relationships between lean body mass, fat mass and peak bone mass in young adults. Osteoporos Int. 2014;25(5):1563-1570.
Bakker NE, van Doorn J, Renes JS, Donker GH, Hokken-Koelega AC. IGF-1 levels, complex formation, and IGF bioactivity in growth hormone-treated children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2015;100(8):3041-3049.
Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000;355(9204):610-613.
Damen L, Grootjen LN, Donze SH, et al. Three years of growth hormone treatment in young adults with Prader-Willi Syndrome previously treated with growth hormone in childhood: effects on glucose homeostasis and metabolic syndrome. Clin Endocrinol. 2020;93(4):439-448.